Abstract
Background COVID-19 is a virus which has lead to a global pandemic. Worldwide, more than 130 countries have imposed severe restrictions, which form part of a set of non-pharmaceutical interventions (NPI)s. We aimed to quantify the country-specific effects of these NPIs and compare them using the Oxford COVID-19 Government Response Tracker (OxCGRT) stringency index, p, as a measure of NPI stringency.
Methods We developed a dual latent/observable Susceptible Infected Recovered Deaths (SIRD) model and applied it on each of 22 countries and 25 states in the US using publicly available data. The observable model parameters were extracted using kernel functions. The regression of the transmission rate, β, as a function of p in each locale was modeled through the intervention leverage, αs, an initial transmission rate, β0 and a typical adjustment time, 
.
Results The world average for the intervention leverage, αs = 0.01 (95% CI 0.0102 - 0.0112) had an ensemble standard deviation of 0.0017 (95% C.I. 0.0014 - 0.0021), strongly indicating a universal behavior.
Discussion Our study indicates that removing NPIs too swiftly will result in the resurgence of the spread within one to two months, in alignment with the current WHO recommendations. Moreover, we have quantified and are able to predict the effect of various combinations of NPIs. There is a minimum NPI level, below which leads to resurgence of the outbreak (in the absence of pharmaceutical and clinical advances). For the epidemic to remain sub-critical, the rate with which the intervention leverage αs increases should outpace that of the relaxation of NPIs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
South African Department of Science and Innovation South African National Research Foundation SA-CERN Program National E-science Postgraduate Teaching and Training Platform IEEE
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
2
Blogs/Media
Author Videos